Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2013

View Archived Issues

New small-molecule enzymatic inhibitors targeting primary human tumors

Adenovirus-based immunotherapy for chronic hepatitis B

New electrochemical immunosensor for diagnosis of inflammatory intestinal disease

Yakult Honsha synthesizes novel protein kinase inhibitors

French team presents new caspase activators

BioSavita and Quanta BioDesign enter collaboration to BioSuperior therapeutics

Dana-Farber and Evotec form oncology collaboration focusing on epigenetic targets

Servier to use Afraxis' ESP Technology for drug discovery

CCT-271850 demonstrates in vitro and in vivo activity

Tolero acquires worldwide license to Sanofi's alvocidib

OGX-427 to be studied as part of combination therapy for pancreatic cancer

Genentech evaluates antibody-drug conjugate for lung and ovarian cancer

Ligand acquires financial rights to portfolio of programs from Selexis

FDA approves use of Actemra in polyarticular juvenile idiopathic arthritis

FDA approves Raptor Pharmaceutical's treatment for nephropathic cystinosis

FDA issues complete response letter declining approval of Probuphine

Roche discloses new CRAC modulators

Novel PDE10A inhibitors prepared by Lundbeck

Enanta Pharmaceuticals synthesizes novel HCV NS5A inhibitors

Ascletis Pharmaceuticals obtains rights to HIV drug in China

DiaMedica begins first-in-human trial of DM-199

Forest Laboratories and Almirall report data from phase III AUGMENT COPD study

Daratumumab receives FDA breakthrough therapy designation

Vyvanse obtains FDA approval for maintenance treatment in children with ADHD

Omadacycline receives another QIDP designation

FDA committee votes against approval of tivozanib

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...